跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 4,988 条关于
“DESTINY-PanTumor02”
全部
4,988
临床试验
4,469
药物
5
机构
14
资讯
500
去年
Trastuzumab Deruxtecan's Expanding Role in HER2-Expressing Solid Tumors
2年前
FDA Grants Priority Review to Enhertu for HER2-Positive Metastatic Solid Tumors
去年
HER2-Directed ADCs Expand Treatment Spectrum Across Solid Tumors
去年
Enhertu Wins 2024 Prix Galien USA Award for Best Biotechnology Product
去年
Evolving Landscape of HER2-Directed Tumor-Agnostic Therapies Shows Promise in Cancer Treatment
去年
Racial Disparities Persist in Triple-Negative Breast Cancer Trials Despite Treatment Advances
9个月前
DESTINY-Ovarian01 Phase 3 Trial Launches to Test ENHERTU as First-Line Maintenance Therapy for HER2-Expressing Ovarian Cancer
2年前
Imfinzi Plus Imjudo Shows Unprecedented Survival in Advanced Liver Cancer
去年
Targeted Therapies Transform Biliary Tract Cancer Treatment as HER2-Directed Agents Gain FDA Approval
5年前
Phase 3 DESTINY-Breast05 Trial Compares Trastuzumab Deruxtecan to T-DM1 in High-Risk HER2+ Early Breast Cancer
第 1 页,共 50 页
上一页
下一页